Heterozygous Inactive Lysine Methyltransferase 2E (KMT2E) variants result in a spectrum of neurodevelopmental disorders, epilepsy, and functional GI disturbances (O’Donnell-Luria et al., 2019). The gene discussed is KMT2E; the disease is epilepsy.